Evidence map›Paper›PMID 40895567›Full record

ReviewFrontiers in immunology2025

High prevalence of the hotspot complement factor I p.Ile357Met pathogenic variant in Tunisian atypical hemolytic uremic syndrome patients: report of three new cases and review of the literature.

Asma Tajouri, Imen Ayadi, Rimeh BenBrahim, Ikram Mami, Abir Boussetta, Hend Jlajla, Yousr Zerzeri, Haifa Arbi Sassi, Jamila Ben Sassi, Hela Sahli and 4 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Asma TajouriDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Imen AyadiDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Rimeh BenBrahimDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Ikram MamiDepartment of Nephrology, La Rabta Hospital, Tunis, Tunisia.
Abir BoussettaDepartment of Pediatrics, Charles Nicolle Hospital, Tunis, Tunisia.
Hend JlajlaDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Yousr ZerzeriDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Haifa Arbi SassiDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Jamila Ben SassiDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Hela SahliLR05SP01 Research Laboratory of Immuno-Rheumatology, La Rabta Hospital, Tunis, Tunisia.
Lilia LaadharDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.
Tahar GargahDepartment of Pediatrics, Charles Nicolle Hospital, Tunis, Tunisia.
Mohamed Karim ZouaghiDepartment of Nephrology, La Rabta Hospital, Tunis, Tunisia.
Maryam Kallel SellamiDepartment of Immunology, La Rabta Hospital, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Atypical Hemolytic Uremic Syndrome (aHUS) is the prototype of renal diseases secondary to dysregulation of the alternative complement pathway. Our previous studies demonstrated that factor I deficiency appears to be common in Tunisian aHUS patients with the recurrence of a rare variant c.1071T>G (p.Ile357Met) localized within exon 10 of the Complement Factor I ( Methods: In this context, we conducted the current study which included 8 adults and three children with suspected aHUS and decreased factor I levels, as well as one relative. We performed molecular investigation by targeting specifically the p.Ile357Met mutation of the Results and discussion: Interestingly, our results showed that the p.Ile357Met mutation was detected in 3 patients out of 11 (two children and one adult) as well as in one relative. Taking into account the high frequency of this pathogenic variant we could confirm that this latter is a hotspot which could be specific to our population. Thus, it would be interesting to look specifically for this variant in any Tunisian aHUS patient with decreased complement factor I level.

Indexed as

Atypical Hemolytic Uremic SyndromeComplement Factor IMutationAdolescentAdultChildChild, PreschoolFemaleGenetic Predisposition to DiseaseHumansInfantInfant, NewbornMaleMiddle AgedPrevalenceTunisiaCFI protein, humanComplement Factor Ialternative pathwayatypical hemolytic uremic syndromecomplement regulatory protein mutationfactor Ithrombotic microangiopathy

Identifiers

PMID40895567
PMCPMC12390990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.